Premium
A novel A97P amino acid substitution in α‐galactosidase A leads to a classical Fabry disease with cardiac manifestations
Author(s) -
Kimura K.,
SatoMatsumura K.C.,
Nakamura H.,
Onodera Y.,
Morita K.,
Enami N.,
Shougase T.,
Ohsaki T.,
Kato M.,
Takahashi T.,
Yamaguchi Y.,
Shimizu H.
Publication year - 2002
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1046/j.1365-2133.2002.04902.x
Subject(s) - transversion , fabry disease , mutation , genotype , biology , genetics , gene , gene mutation , microbiology and biotechnology , disease , medicine
Summary Background Fabry disease results from a genetic deficiency of α‐galactosidase A (GLA) activity. Phenotype–genotype correlations in this condition have not as yet been fully elucidated. Objectives To report a case of a male patient with classical Fabry disease and his mother, a heterozygous female with Fabry disease, showing cardiac involvement, and to identify the underlying GLA gene mutation in this particular phenotype. Patients/methods Genomic DNA was extracted from the patient, his mother and the unaffected family members. Biopsy specimens of skin, heart and kidney were examined using light and electron microscopy. The mutation was identified by polymerase chain reaction and direct sequencing and was confirmed by restriction enzyme fragment length polymorphism. Results The G→C transversion was identified in codon 97 of the GLA gene and resulted in an A97P amino acid substitution that was a novel pathogenic GLA gene mutation. The male patient who had classical Fabry disease was hemizygous and his mother was heterozygous for this mutation. Conclusions These results indicate that the A97P amino acid substitution in GLA might tend to induce classical Fabry disease.